PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  05:02 2022-06-28 pm EDT
50.73 USD   -2.23%
05:03pFDA advisers recommend updating COVID booster shots for fall
AQ
01:38pSECTOR UPDATE : Health Care
MT
08:08aPFIZER INC : JP Morgan sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER INC : Goldman Sachs reiterates its Neutral rating

05/25/2022 | 08:36am EDT

Initially Neutral on the company, Goldman Sachs's analyst Chris Shibutani maintained his recommendation. The target price remains unchanged at USD 51.


© MarketScreener with dpa-AFX Analyser 2022
All news about PFIZER, INC.
05:03pFDA advisers recommend updating COVID booster shots for fall
AQ
01:38pSECTOR UPDATE : Health Care
MT
08:08aPFIZER INC : JP Morgan sticks Neutral
MD
08:06aPfizer, Roivant Sciences Launch New Joint Biotechnology Company Focused on Autoimmune D..
MT
06:01aRoivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for ..
BU
06/27SECTOR UPDATE : Health Care Stocks Posting Modest Monday Gains
MT
06/27SECTOR UPDATE : Health Care Stocks Rising in Defensive Afternoon Trade
MT
06/27US grapples with whether to modify COVID vaccine for fall
AQ
06/27Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Ana..
AQ
06/27Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate Hi..
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 103 B - -
Net income 2022 35 924 M - -
Net cash 2022 12 888 M - -
P/E ratio 2022 8,63x
Yield 2022 3,13%
Capitalization 291 B 291 B -
EV / Sales 2022 2,69x
EV / Sales 2023 3,45x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 51,88 $
Average target price 57,26 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-12.63%289 466
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
ROCHE HOLDING AG-14.92%272 090
ABBVIE INC.12.51%269 202
NOVO NORDISK A/S8.16%253 053